BIOENGINEERED ARTIFICIAL SKIN MARKET ANALYSIS

Global bioengineered artificial skin market is value at US$ 3.32 Billion In 2023 and is expected to grow at a compound annual growth rate (CAGR) of 16.9% to reach US$ 9.92 Billion by 2030. Factors such as increasing healthcare spending, rising demand for regenerative medicine, and technological advancements in skin substitute products are also expected to drive the growth of the bioengineered artificial skin market.

The global bioengineered artificial skin market is expected to experience significant growth in the near future, driven by increasing demand for skin substitutes for wound healing and reconstruction, and technological advancements in skin substitute products.

Global Bioengineered Artificial Skin Market Regional Insights

• North America is expected to be the largest market for bioengineered artificial skin due to the presence of a well-established healthcare infrastructure, high adoption of advanced healthcare technologies, and increasing government initiatives to support regenerative medicine research. The U.S. is expected to be the largest market in North America due to factors such as high healthcare spending, increasing prevalence of chronic wounds and skin diseases, and increasing awareness about the benefits of bioengineered skin substitutes. The region holds a substantial percentage of the market share, accounting for approximately 40.2%.
• Europe is also expected to be a significant market for bioengineered artificial skin due to the increasing prevalence of chronic skin diseases, rising geriatric population, and growing demand for regenerative medicine. The U.K., Germany, and France are expected to drive the growth of the bioengineered artificial skin market. Europe holds around 30.5% of the market share.
• Asia Pacific is expected to be the fastest-growing market for bioengineered artificial skin, which is driven by the increasing demand for regenerative medicine, increasing healthcare spending, and rising awareness about the benefits of bioengineered skin substitutes. Japan, China, and India are expected to drive the market growth of the bioengineered artificial skin. Asia Pacific accounts for approximately 21.1% of the market share.

Figure 1. Global Bioengineered Artificial Skin Market, By Region

To learn more about this report, request a free sample copy

Analysts’ Views on Global Bioengineered Artificial Skin Market:

• The global market for bioengineered artificial skin is expected to grow substantially in the coming years. The rising incidence of severe burn injuries worldwide will be a major driver for this market. Artificial skin offers an effective alternative to skin grafts for the treatment of burns. Its ability to regenerate damaged tissue and prevent scarring provides clinicians an attractive option over conventional treatments. Additionally, advancements in tissue engineering and regenerative medicine have enabled scientists to develop skin substitutes that closely resemble natural skin both structurally and functionally.
• However, high product costs pose a significant challenge to widespread adoption. Developing artificial skin involves complex and costly research and manufacturing processes. Ensuring long-term viability and minimizing rejection risks also require extensive clinical testing. With many alternative treatments available, price sensitivity will impact purchasing decisions, especially in cost-conscious developing regions. More funding for research from private and public sources can help lower costs through economies of scale.

Global Bioengineered Artificial Skin Market Drivers:

• Increasing prevalence of chronic wounds and skin diseases: The rising prevalence of chronic wounds and skin diseases such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers is driving the demand for bioengineered artificial skin substitutes. This is due to the products that offer a more effective and efficient treatment option as compared to traditional wound care treatments. For instance, on September 4, 2023, according to MDPI(Multidisciplinary Digital Publishing Institute) Biomedicines publication “Chronic Wound Management: From Gauze to Homologous Cellular Matrix”, the latest data collected in 2022 showed that the global prevalence of chronic wounds lies at 1.67 per 1,000 population. Most chronic wounds refer to chronic leg ulcers, and their computed prevalence is 1.51 per 1,000 population.
• Rising incidence of burn injuries: Rising incidence of burn injuries, especially in developing nations, is a major factor boosting the market growth of bioengineered artificial skin. For instance, on October 12, 2023, according to data from the World Health Organization (WHO) published in ‘Burns’, over 11 Bn burn injuries require medical treatments which occur worldwide in every year. The severity of burns has also increased over the years due to industrial and road accidents. Conventional skin grafts are often not sufficient to treat extensive burns. covering over 50% of the total body surface area. This has increased the demand for tissue-engineered skin substitutes that can help manage complicated burns.
• Rising demand and advancement in regenerative medicine: The field of regenerative medicine is growing rapidly, and bioengineered artificial skin is a critical component of this field. Bioengineered skin substitutes are used in tissue engineering, wound healing, and other regenerative medicine applications, which are expected to drive the growth of the bioengineered artificial skin market. For instance, in January 2022, AVITA Medical, Inc., a regenerative medicine company announced, developing and commercializing a Recell system technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, has completed enrollment into its pivotal trial for the use of the RECELL System for soft-tissue reconstruction.

Global Bioengineered Artificial Skin Market Opportunities:

• Increasing adoption in emerging markets: Emerging markets, such as Asia Pacific and Latin America, present significant growth opportunities for the bioengineered artificial skin market. As healthcare infrastructure and awareness about advanced wound care products increase in these regions, the demand for bioengineered skin substitutes is expected to grow. For instance, in January, 2022, Convatec Group Plc., a U.K. based global medical solutions company, which is focused on the management of chronic conditions announced, that it has entered into a definitive agreement to acquire Triad Life Sciences Inc., a U.S.-focused medical device company, that develops biologically-derived innovative products to address unmet clinical needs in surgical wounds, chronic wounds, and burns. It strengthens Convatec Group Plc.,’s Advanced Wound Care position in Europe and U.S. region.
• Collaborations and partnerships: Collaborations and partnerships between companies and academic institutions are expected to drive innovation in the development of advanced bioengineered skin substitutes. These collaborations can also help expand the reach of bioengineered skin substitutes into new markets and applications. For instance, in June 2021, Smith & Nephew, U.K. based medical device company announced the acquisition of Integra LifeSciences' global medical device manufacturing company’s Orthopedics business, which includes the development of bioengineered skin substitutes for wound care and tissue repair.
• Adoption of 3D printing technology: The adoption of 3D printing technology in the development of bioengineered skin substitutes presents a significant opportunity for the market growth. 3D printing technology can be used to create highly precise and customized skin substitutes, improving treatment outcomes, and reducing healing time. For instance, on February 2, 2023, according to the article published in the journal ‘REVIEWS ON ADVANCED MATERIALS SCIENCE’, there are new technological advancement like 3D bio printing which can generate skin substitutes with improved quality and high complexity for wound healing and in vitro disease modeling.\

Global Bioengineered Artificial Skin Market Trends:

• Development of advanced skin substitutes: The development of advanced bioengineered skin substitutes, including bilayered and trilayered substitutes, is a significant trend in the market. These products offer improved wound healing and tissue regeneration properties, leading to increased demand and adoption for regenerative based medicine. For instance, in August 2023, according to an article published by Frontiers in medicine Journal ‘Skin substitutes as treatment for chronic wounds’, ABnion-derived skin substitutes include dehydrated human aBnion allografts (dHAM), and dehydrated human aBnion chorion tissue allografts (dHACM) poses advantages of pain relieving qualities, antibacterial and non-immunogenic properties, and reduction in inflammation and scar development in treatment of diabetic foot ulcers (DFU) and venous leg ulcers (VLU).
• Rising preference for biosynthetic skin substitutes: Biosynthetic skin substitutes are engineered substitutes created from both biologic and synthetic materials that can closely mimic natural skin. Bioengineered Skin grafts offer improved compatibility with the human body as compared to fully synthetic skin grafts. This rising demand is driven by the ability of biosynthetic skin to integrate well with the native tissues and induce natural healing processes. They allow for regeneration of functional skin tissue and hence improve the clinical outcomes for patients who require treatment for burns and other skin wounds. For instance, as per Fact sheet of year 2020 published by American Burn Association, approximately 450,000 burns requiring medical attention occur each year in theU.S. Biosynthetic skin grafts can potentially help in the treatment of such patients and improve survival and recovery rates.
• Growing focus on sustainability: The trend towards sustainability is also impacting the bioengineered artificial skin market, with increasing demand for eco-friendly and sustainable products. This trend is expected to drive the development of bioengineered skin substitutes made from sustainable and biodegradable materials. The increasing focus on sustainability and environment protection has pushed research and development (R&D) in bioengineered artificial skin. With increasing awareness about minimizing medical waste, researchers are exploring ways to develop bioengineered skin that is biodegradable and causes less environmental impact. Some of the leading companies in this sector are investing in producing artificial skin from biological materials like collagen and fibrin that can degrade naturally inside the human body once the healing process is complete. This allows avoiding disposal of synthetic skin patches in landfills or incineration after usage, making the treatment more eco-friendly. For instance, in 2020, according to clinical data published by Intercytex, U.K based regenerative medicine company in 2020, the bioengineered skin substitute of the company, dermaPure, gets incorporated into the patients' own regenerated skin within 4-6 weeks in 90% of acute wound cases, making the treatment fully biodegradable. Such shifts towards bioabsorbable substitutes demonstrate how sustainability concerns are reshaping innovation in this sector to develop greener medical alternatives.

Figure 2. Global Bioengineered Artificial Skin Market, By Product Type

To learn more about this report, request a free sample copy

Global Bioengineered Artificial Skin Market Restraints:

• High cost of bioengineered skin substitutes: The cost of bioengineered skin substitutes is relatively high compared to traditional wound care treatments, which may limit adoption in certain markets and patient populations. For instance,
• Regulatory challenges: The development and commercialization of bioengineered skin substitutes are subject to regulatory approval, which can be a lengthy and expensive process. Regulatory challenges can slow down the development of new products and limit market entry. For instance, in December 2020, according to the journal published by ‘Burn Care and Research’ publication ‘Navigating the Regulatory Pathways and Requirements for Tissue’the regulation of tissue-engineered products in the U.S.Occurs by one of several pathways established by the U.S. Food and Drug Administration (U.S. FDA), including a Biologics License Application (BLA), a 510(k) (Class I and Class II devices), Premarket Approval (Class III devices), or a human cells, tissues, and cellular and tissue-based products designation. Key differentiators among these regulatory classifications include the amount and type of data required to support a filing. For example, a BLA requires a clinical trial(s) and evaluation of safety and efficacy by the Center for Biologics Evaluation and Research.
• Counterbalance: As a result, the market players should carry out programs to increase awareness of the bioengineered artificial skin, so that there is availability of donors in the said market. Also, the cost of such products should be made as such that it is easily affordable by the masses.

Global Bioengineered Artificial Skin Market Recent Developments

New product launches

1. In June 2021, Stratatech Corporation, a subsidiary of Mallinckrodt Pharmaceuticals, launched the StrataGraft, a unique non-biologic, cellularized, bioengineered tissue designed to treat severe burns.
2. In March 2021, Avita Medical, U.S. based clinical and commercial company developing and marketing a range of respiratory and regenerative products, launched the Recell System in the U.S. The recell system is a spray-on skin substitute that uses a patient's own skin cells to treat acute burns.
3. In February 2021, TissueTech, privately-held biotechnology company launched the ABniox RT, a new aBniotic membrane product designed for use in wound healing and tissue repair.

Acquisition and partnerships

1. In June 2021, Smith & Nephew, Global medical device company announced the acquisition of Integra LifeSciences' global medical device manufacturing company’s Extremity Orthopedics business, which includes the development of bioengineered skin substitutes for wound care and tissue repair.
2. In March 2021, TissueTech announced a strategic partnership with Corneal Associates of New Jersey, U.S. to offer a new regenerative medicine solution for corneal injuries using bioengineered tissues.
3. In December 2020, Organogenesis Holdings Inc., leading regenerative medicine company, announced the acquisition of NuTech Medical, a company focused on developing innovative wound care products, including bioengineered skin substitutes.

Top Companies in Global Bioengineered Artificial Skin Market

• Genoskin 
• Smith and Nephew Inc
• Genzyme Biosurgery
• Vericel Corporation
• AROA BIOSURGERY LIMITED
• Integra LifeSciences Corp
• COOK BIOTECH
• Mölnlycke Health Care AB
• Avita Medical
• MiMedx Group, Inc.
• Organogenesis Holdings Inc

*Definition: Bioengineered artificial skin refers to synthetic substitutes created through bioengineering techniques to mimic the structure and functions of natural human skin. It is used in medical applications, primarily for wound healing and skin regeneration. These products are developed by use of living cells, scaffolds, and growth factors of skin to promote tissue repair and recovery.